

Collaborative Working Project executive summary

Project title	Post transplant and GvHD patient pathway mapping and service evaluation with Addenbrookes Hospital.
Partner organisation/s	Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ Sanofi 410 Thames Valley Park Drive, Reading RG6 1PT
Project rationale	<p>Addenbrookes Hospital is commissioned by NHS England and provides the primary bone marrow transplantation service for the East Anglian region. The Addenbrookes transplant service services a large geographical area and receives referrals from seven hospitals across the East Anglian region. The service currently performs approximately 100 allogeneic transplants, 100-110 autologous transplants and 40 CAR-T procedures a year. Due to the large geographical coverage and number of patients being referred, the current service capacity is under severe pressure.</p> <p>Currently, the follow up of transplant patients happens within one clinic, which includes acute patients (within 100 days), longer-term follow-up patients and patients with chronic GvHD. It is possible that separation of patients may lead to greater efficiency. In addition, shared care with referring centres is relatively ad hoc despite the presence of shared care policies.</p>
Project period	<i>Q1 2025 to Q4 2025</i>
Project objectives	<p>The project will aim to deliver the following objectives:</p> <ul style="list-style-type: none"> • A review of the current service model for follow-up of transplant patients • Map and evaluate the current post transplant, late affects clinics and GvHD patient pathways and service provision to identify service gaps and identify variation in patient care. • Evaluate the existing discharge process to ensure appropriate patients are identified and discharged back to their home trust with access to high quality follow up support. • To develop and rollout education resources to referring trusts to ensure they have the adequate skills and resources to maintain patients who have been discharged post- transplant as required.

	<p>Provide an options appraisal for service improvements and supporting information for business cases required to secure additional funding required for changes in the pathway or service provision.</p> <p>The proposed benefits for patients, NHS and Sanofi are as follows:</p> <p>Patients:</p> <ul style="list-style-type: none"> • Improvement in co-ordination of care and patient experience. • Support improved access to treatment and provide a cohesive treatment approach. • Streamlined care ensuring more effective transit through the BMT service. • Provide a positive patient experience when discharged to local supportive care. <p>NHS:</p> <ul style="list-style-type: none"> • Obtain greater clarity of the existing pathway and where the gaps and issues exist. • Optimise the service offerings to patients provided through the current GvHD pathway. • Provide enhanced patient and staff educational input. • Improve regular review of patients care and symptoms allowing faster identification of therapeutic issues and improving treatment optimisation. • Potential to free up Consultant and BMT nurse time through an improved patient discharge programme, releasing Consultant/clinic capacity to see other patients. <p>Sanofi:</p> <ul style="list-style-type: none"> • Greater clarity of the pressure points and priorities for a national specialist Bone Marrow Transplant Centre, enabling us to tailor our offerings in the future. • Greater clarity of the problems surrounding the services ability to deliver and tailor services to patient needs and provide learning to improve Sanofi's ability to support other BMT services within the UK. <p>This project will be completed by pooling resources at a total cost of £18,189. (Sanofi indirect costs £9,460 and NHS indirect cost £8,729)</p>
<p>Contact details</p>	<p>Dr Andrew King - Consultant Haematologist & Clinical Lead Haematology/Oncology, Addenbrookes Hospital</p> <p>andrew.king20@nhs.net</p>

	<p>Debbie Woods – Country Medical Lead & Head of Gen Med UKIE, Sanofi</p> <p>GB-marketaccess@sanofi.com</p>
--	---